

Bri Biosciences Limited
騰盛博藥生物科技股份有限公司

(A company incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

(Stock Code 股份代號: 2137)

NOTIFICATION LETTER 通知信函

Dear Non-Registered Shareholder⁽¹⁾,

September 26, 2022

Bri Biosciences Limited (the “Company”)
– Notification of publication of 2022 Interim Report (the “Current Corporate Communication”)

The Current Corporate Communication of the Company, in both English and Chinese versions, is available on the Company’s website at <http://www.briibio.com> and the website of The Stock Exchange of Hong Kong Limited at <http://www.hkexnews.hk>.

If you wish to receive printed version of the Current Corporate Communication, please complete the Request Form on the reverse side and return it to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the mailing label (for pre-paid postage in Hong Kong) at the bottom of the Request Form.

Please note that by completing and returning the Request Form to request for the printed version of the Current Corporate Communication, you will expressly indicate that your instruction to receive printed version will apply to all future Corporate Communications⁽²⁾ of the Company to be sent to you until you notify the Company’s branch share registrar and transfer office in Hong Kong to the contrary or you cease to hold any shares of the Company.

Should you have any queries relating to this notification letter, please do not hesitate to call the enquiry hotline at (852) 2980 1333 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding public holidays).

Yours faithfully,
For and on behalf of
Bri Biosciences Limited
Dr. Zhi Hong
Chairman

Notes: (1) This notification letter is addressed to “Non-registered Shareholder”, which means such person or company whose shares are held in the Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications.

(2) Corporate Communication(s) refer to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to: (a) directors’ reports, annual accounts together with the auditors’ reports and, where applicable, summary financial reports; (b) interim reports and, where applicable, summary interim reports; (c) notices of meetings; (d) listing documents; (e) circulars; (f) proxy forms; and (g) reply slips.

各位非登記股東⁽¹⁾：

騰盛博藥生物科技股份有限公司 (「本公司」)
– 刊發2022年中期報告 (「本次公司通訊」) 的通知

本公司之本次公司通訊，均備有英文及中文版本，已登載於本公司網站<http://www.briibio.com>及香港聯合交易所有限公司之網站<http://www.hkexnews.hk>。

如閣下欲收取本次公司通訊之印刷本，請填妥本函背面之申請表格及使用申請表格底部隨附之郵寄標籤（已預付在香港投寄之郵費）寄回本公司之香港股份過戶登記分處卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓。

請注意，當閣下填寫及寄回申請表格以索取本次公司通訊之印刷本後，即表示確認閣下收取印刷本之指示將適用於本公司今後所有之公司通訊⁽²⁾，直至閣下通知本公司之香港股份過戶登記分處另外之安排或停止持有本公司的股份。

閣下如就本通知信函有任何疑問，請於辦公時間內致電查詢熱線(852) 2980 1333，辦公時間為星期一至星期五（香港公眾假期除外）上午9時正至下午6時正。

代表
騰盛博藥生物科技股份有限公司
主席
Zhi Hong 博士
謹啟

2022年9月26日

附註： (1) 此函件乃向本公司之非登記之股東（指股份存放於中央結算及交收系統的人士或公司，並透過香港中央結算有限公司不時向本公司發出通知，希望收取公司通訊）發出。

(2) 公司通訊指由本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；(f)代表委任表格；及(g)確認回條。

Request Form 申請表格

To: **Brii Biosciences Limited (the "Company")**
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

致: 騰盛博藥生物科技有限公司 (「本公司」)
卓佳證券登記有限公司轉交
香港夏愨道16號
遠東金融中心17樓

I/We would like to receive the current and future Corporate Communications⁽¹⁾ of the Company in printed copies.

本人 / 吾等要求索取本公司本次及今後刊發之公司通訊印刷本⁽¹⁾。

Signature:

簽署:

(English 英文)

Date:

日期:

(Chinese 中文)

Contact Phone

Number:

聯絡電話:

Notes 附註:

- Corporate Communication(s) refer to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to: (a) directors' reports, annual accounts together with the auditors' reports and, where applicable, summary financial reports; (b) interim reports and, where applicable, summary interim reports; (c) notices of meetings; (d) listing documents; (e) circulars; (f) proxy forms; and (g) reply slips.
公司通訊指由本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；(f)代表委任表格；及(g)確認回條。
- By completing and returning this Request Form to request for the printed copy of the Current Corporate Communication, you have expressly indicated that you prefer to receive all future Corporate Communications of the Company in printed copies.
當閣下填寫及寄回此申請表格以索取本次刊發之公司通訊印刷本後，即表示閣下確認擬收取本公司今後刊發的所有公司通訊的印刷本。

(Please cut along the dotted line. 請沿虛線剪下。)



Mailing Label 郵寄標籤

Please cut the mailing label and stick this on an envelope to return the Request Form to us.

No postage stamp is required for local mailing

當閣下寄回此申請表格時，請將此郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票

Tricor Investor Services Limited
卓佳證券登記有限公司
Freepost No. 簡便回郵號碼: 10 GPO
Hong Kong 香港
Brii Bio (2137)